BioCryst Pharmaceuticals ...

AI Score

0

Unlock

7.95
-0.06 (-0.75%)
At close: Jan 28, 2025, 1:40 PM

Company Description

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines.

The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika.

The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd.

BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc. logo
Country United States
IPO Date Mar 4, 1994
Industry Biotechnology
Sector Healthcare
Employees 536
CEO Jon P. Stonehouse

Contact Details

Address:
4505 Emperor Boulevard
Durham, North Carolina
United States
Website https://www.biocryst.com

Stock Details

Ticker Symbol BCRX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000882796
CUSIP Number 09058V103
ISIN Number US09058V1035
Employer ID 62-1413174
SIC Code 2836

Key Executives

Name Position
Jon P. Stonehouse Chief Executive Officer, President & Executive Director
Alane P. Barnes Senior Vice President, Chief Legal Officer & Corporate Secretary
Anthony J. Doyle Senior Vice President, Chief Financial Officer & Interim Principal Accounting Officer
Stephanie Angelini Chief People Officer
Charles K. Gayer Senior Vice President & Chief Commercial Officer
Dr. Helen M. Thackray FAAP, M.D. Chief Research & Development Officer
Dr. William P. Sheridan MBBS Chief Development Officer
Dr. Yarlagadda S. Babu Ph.D. Chief Discovery Officer
Jinky Ang Rosselli Chief Data & Insights Officer
John D. Bluth Chief Communications Officer

Latest SEC Filings

Date Type Title
Jan 13, 2025 8-K Current Report
Jan 10, 2025 8-K Current Report
Jan 08, 2025 8-K Current Report
Dec 23, 2024 4 Filing
Dec 23, 2024 4 Filing
Dec 23, 2024 4 Filing
Dec 23, 2024 4 Filing
Dec 23, 2024 4 Filing
Dec 17, 2024 4 Filing
Dec 17, 2024 4 Filing